- Home
- VEEE vs ONCT Comparison
VEEE vs ONCT Comparison
Compare VEEE & ONCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEEE
- ONCT
- Stock Information
- Founded
- VEEE 1994
- ONCT N/A
- Country
- VEEE United States
- ONCT United States
- Employees
- VEEE N/A
- ONCT N/A
- Industry
- VEEE Marine Transportation
- ONCT Biotechnology: Pharmaceutical Preparations
- Sector
- VEEE Industrials
- ONCT Health Care
- Exchange
- VEEE Nasdaq
- ONCT Nasdaq
- Market Cap
- VEEE 4.7M
- ONCT 4.3M
- IPO Year
- VEEE 2021
- ONCT N/A
- Fundamental
- Price
- VEEE $0.44
- ONCT $1.13
- Analyst Decision
- VEEE
- ONCT Buy
- Analyst Count
- VEEE 0
- ONCT 3
- Target Price
- VEEE N/A
- ONCT $10.00
- AVG Volume (30 Days)
- VEEE 1.3M
- ONCT 157.5K
- Earning Date
- VEEE 11-14-2024
- ONCT 11-06-2024
- Dividend Yield
- VEEE N/A
- ONCT N/A
- EPS Growth
- VEEE N/A
- ONCT N/A
- EPS
- VEEE N/A
- ONCT N/A
- Revenue
- VEEE $20,852,002.00
- ONCT $2,161,000.00
- Revenue This Year
- VEEE $76.99
- ONCT $113.76
- Revenue Next Year
- VEEE N/A
- ONCT N/A
- P/E Ratio
- VEEE N/A
- ONCT N/A
- Revenue Growth
- VEEE N/A
- ONCT 227.92
- 52 Week Low
- VEEE $0.33
- ONCT $1.03
- 52 Week High
- VEEE $1.77
- ONCT $13.20
- Technical
- Relative Strength Index (RSI)
- VEEE 39.83
- ONCT 37.09
- Support Level
- VEEE $0.44
- ONCT $1.03
- Resistance Level
- VEEE $0.52
- ONCT $1.30
- Average True Range (ATR)
- VEEE 0.06
- ONCT 0.19
- MACD
- VEEE -0.00
- ONCT -0.01
- Stochastic Oscillator
- VEEE 15.69
- ONCT 13.70
About VEEE Twin Vee PowerCats Co.
Twin Vee PowerCats Co is a designer, manufacturer, and marketer of recreational and commercial power catamaran boats to use for fishing, diving and water skiing and commercial activities including transportation, eco-tours, fishing, and diving expeditions. Its revenue is derived from the sale of boats, motors, and trailers to its independent dealers. It has organized its business into three operating segments: The gas-powered boat segment, which manufactures and distributes gas-powered boats; The electric-powered boat segment, which is developing fully electric boats, through its controlling interest subsidiary, and its franchise segment, which is developing a standard product offering and will be selling franchises across the United States through its wholly-owned subsidiary.
About ONCT Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.